Pfizer (PFE, Financial) has finalized the sale of its entire holding in Haleon (HLN, Financial), generating approximately £2.5 billion ($3.24 billion), Reuters reported Wednesday, citing a bookrunner involved in the transaction.
The pharmaceutical company, which co-founded Haleon alongside British drugmaker GSK (GSK, Financial) in 2019, offloaded around 662 million shares, equal to a 7.3% stake. The shares were priced at 385 pence each.
As part of the deal, Haleon repurchased 44 million shares directly from Pfizer, while institutional investors acquired the remaining 618 million.
Bloomberg News previously disclosed on Tuesday that Pfizer planned to fully exit its stake in Haleon, a process that had been underway since the company's separation from GSK in 2022.
With GSK having completed its divestment in May, BlackRock Investment Management (UK) Ltd., a subsidiary of BlackRock (BLK, Financial), is set to become Haleon's largest shareholder, holding over 5% of its shares, according to Reuters, citing LSEG data.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。